All In Biotech

Drug Trial Radar · NCT05499130

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 290 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

290

Actual

Start

Sep 30, 2022

Primary completion

Nov 12, 2024

Study completion Nov 12, 2024

Sponsor

Sponsor type
Industry
Collaborators
Sanofi
First posted
Aug 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to characterize the efficacy TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's Disease (CD)) as assessed by induction of clinical remission (UC) and endoscopic response (CD) at week 14. Secondary objectives: * To evaluate the efficacy of 2 different doses of TEV-48574 as assessed by multiple standard measures * To evaluate the safety and tolerability of 2 different doses of TEV-48574 * To evaluate the immunogenicity of 2 different dioses of TEV-48574 The study will consist of a screening period of up to 6 weeks (42 days), a 14-week treatment period, and a 4-week follow-up period.

Conditions

  • Crohn Disease
  • Colitis, Ulcerative

Interventions

  • TEV-48574Drug

    Subcutaneous infusion

  • PlaceboDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Moderate to Severe UC Who Showed Clinical Remission as Defined by the MMSTime frame: Week 14
  2. Number of Participants With Moderate to Severe CD Who Showed an Endoscopic Response as Defined by the SES-CDTime frame: Baseline to Week 14

Locations

164 sites in 19 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 15568

    Sun City, Arizona

  • Teva Investigational Site 15556

    San Diego, California

  • Teva Investigational Site 15747

    San Diego, California

  • Teva Investigational Site 15357

    Kissimmee, Florida

  • Teva Investigational Site 15563

    Miami, Florida

  • Teva Investigational Site 15365

    Miami, Florida

  • Teva Investigational Site 15748

    Miami, Florida

  • Teva Investigational Site 15375

    Orlando, Florida

  • Teva Investigational Site 15359

    Pinellas Park, Florida

  • Teva Investigational Site 15566

    Glenview, Illinois

  • Teva Investigational Site 15567

    Gurnee, Illinois

  • Teva Investigational Site 15574

    New Albany, Indiana

  • Teva Investigational Site 15362

    Iowa City, Iowa

  • Teva Investigational Site 15367

    Kansas City, Kansas

  • Teva Investigational Site 15368

    Louisville, Kentucky

  • Teva Investigational Site 15575

    Louisville, Kentucky

  • Teva Investigational Site 15363

    Columbia, Maryland

  • Teva Investigational Site 15358

    Liberty, Missouri

  • Teva Investigational Site 15373

    St Louis, Missouri

  • Teva Investigational Site 15369

    Las Vegas, Nevada

  • Teva Investigational Site 15558

    North Massapequa, New York

  • Teva Investigational Site 15370

    Chapel Hill, North Carolina

  • Teva Investigational Site 15750

    Beavercreek, Ohio

  • Teva Investigational Site 15557

    Greenville, South Carolina

  • Teva Investigational Site 15573

    Cordova, Tennessee

  • Teva Investigational Site 15360

    Austin, Texas

  • Teva Investigational Site 15371

    Dallas, Texas

  • Teva Investigational Site 15569

    Garland, Texas

  • Teva Investigational Site 15559

    Harlingen, Texas

  • Teva Investigational Site 15366

    Katy, Texas

  • Teva Investigational Site 15743

    Lubbock, Texas

  • Teva Investigational Site 15372

    Pearland, Texas

  • Teva Investigational Site 15374

    San Antonio, Texas

  • Teva Investigational Site 15565

    Southlake, Texas

  • Teva Investigational Site 15361

    Tyler, Texas

  • Teva Investigational Site 15364

    Salt Lake City, Utah

  • Teva Investigational Site 33055

    Innsbruck, Austria

  • Teva Investigational Site 33056

    Vienna, Austria

  • Teva Investigational Site 37134

    Edegem, Belgium

  • Teva Investigational Site 37133

    Liège, Belgium

Showing 40 of 164 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.